Daewoong Pharma said it has submitted a New Drug Application (NDA) to the Saudi Food and Drug Authority (SFDA) for Envlo tablets (ingredient: enavogliflozin), a diabetes treatment and Korea's 36th new drug.
The treatment is the first locally developed sodium-glucose cotransporter 2 (SGLT-2) inhibitor.
According to IQVIA, a global drug market research firm, Saudi Arabia's diabetes drug market size was worth 1.22 trillion won ($919.5 million) in 2022, making it the largest in the Middle East. The market for SGLT-2 inhibitors, of which Envlo is a part, is valued at 153.4 billion won and has grown more than twofold since 2020.
Apart from Saudi Arabia, Daewoong has also completed the NDA for Envlo in four Association of Southeast Asian Nations (ASEAN) countries – Indonesia, Thailand, the Philippines, and Vietnam -- and will continue to accelerate its global expansion with the goal of entering 15 countries by 2025 and 50 countries by 2030.
"The Saudi Arabia approval submission for Envlo comes less than half a year after the company applied for approval in Indonesia, Philippines, Thailand, and Vietnam in March," Daewoong Pharma CEO Jeon Seng-ho said. "We will do our best to make Saudi Arabia a bridgehead for entering the Middle East market and grow Envlo into a global blockbuster drug."
Related articles
- Daewoong's Q2 operating profit up by 7.8% year-on-year
- Daewoong wins license for SGLT2i+metformin combo Envlomet
- Daewoong to turn Envlo into blockbuster with ₩100 billion sales in 3 years
- Daewoong Pharmaceutical signs 3 technology export deals totaling over ₩1 trillion
- Daewoong Pharmaceutical releases SGLT-2 inhibitor Envlo to treat diabetes
- Daewoong’s botulinum toxin wins 'world’s 1st' nod to treat square jaw
- Huons expands free support for CGM device to ease financial strain on diabetic patients
- Daewoong seeks to conduct phase 3 study on Envlo combo to treat diabetes
- Daewoong wins Nabota’s migraine patent in US until 2041